

# Vaishali Pharma Ltd.

(Formerly known as Vaishali Pharma Pvt. Ltd.)



**CORPORATE & REGISTERED OFFICE :**  
706-709, 7th Floor, Aravali Business Centre,  
R. C. Patel Road, Off. Sodawala Lane,  
Borivali (West), Mumbai-400 092.  
Tel.: +91-22-4217 1819 (30 Lines)  
Fax: +91-22-2892 8833  
E-mail : [info@vaishalipharma.com](mailto:info@vaishalipharma.com)  
[export@vaishalipharma.com](mailto:export@vaishalipharma.com)  
CIN - L52310MH2008PLC181632

16<sup>th</sup> October, 2020

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051

**Stock Code: VAISHALI**

Dear Sir/Madam,

**SUB: PRESS RELEASE ON KEY DEVELOPMENTS.**

We refer to captioned subject, we would like to inform you that the Company is amongst the leading players in the supply of pharma products such as Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products.

On the business front, the Company has made remarkable progress. The Company has received the Orders for supply of various healthcare products in Gulf Countries and we look forward to develop and expand the brands of Vaishali Pharma Limited and help the clientele to fight amidst COVID-19 pandemic.

Please find enclosed herewith a copy of Press Release giving information about the same and many more.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,  
**For Vaishali Pharma Limited**

**Atul Arvind Vasani**  
**Managing Director**



### Press Release

**Mumbai, October 16, 2020:** Vaishali Pharma Limited (NSE:- VAISHALI), a Mumbai based company, is extremely proud to update our esteemed stakeholders about its pharmaceuticals products related to Covid-19 and Immunity Boosters for domestic as well as international markets with an objective to boost immunity towards various prevailing diseases. The Company is showing consistent agility and innovation by meeting the needs of its customers in both domestic and international markets especially the recent requirements emerging from COVID-19.

Vaishali Pharma has progressed significantly by introducing Vitamin C supplements in different variants viz. - Vitamin C chewable tablets, Vitamin C effervescent tablets and Vitamin C with zinc combo which is easiest way to boost the Vitamin C intake in case of deficiencies. Vitamin C is beneficial in many contexts like boosting antioxidant levels, lowering blood pressure, protecting against gout attacks, improving iron absorption, reducing heart disease and dementia. The Company is amongst the leading players in the supply of pharma products such as Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products to help the clientele to fight amidst COVID-19 pandemic. The company has launched these products worldwide in 11 countries including India. The Company has also initiated supply of its pharmaceutical products in Gulf Countries such as Iraq, Oman, UAE etc.

Adapting quickly to the ever-evolving demands, we have emerged as one of the fastest growing organization in the export of Pharmaceutical products across the globe, and currently the company has undertaken to export pharmaceutical, surgical and veterinary products to various countries.

It has taken proactive measures to launch necessary products to meet the requirements arisen from COVID-19 such as sanitizers, PPE kit, face shields and face masks etc. This is another step forward by the company, as the recently launched Vitamin C supplement can help in boosting immunity to fight against COVID-19.

Vaishali Pharma has predominantly built portfolio into immunity products since its inception apart from range of other products in each and every segment. The company is striving hard to double the product range in coming years and working in that direction with registration of products in various countries.

#### **ABOUT VAISHALI PHARMA LIMITED:**

Vaishali Pharma Limited (NSE: VAISHALI), abided by the norms of extending uncompromised quality products, has raised the standards of the Pharmaceutical & Healthcare industry time and again. Through unwavering dedication, consistent efforts and endless innovation we enjoy an Export House status. Company's products' quality is certified by ISO 9001:2015 certification for the Quality Management from ISC Global.

Incorporated in the year 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading

players in the supply of pharma products – Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 150+ formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The company has built a robust pipeline of around 250 Dossiers. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai. Further widening our reach overseas, the Company made a joint venture with D.R. Congo & Kenya based Company. The Company exports to countries like Russia, Dubai, Nigeria, Kenya, Ukraine, Ethiopia, Costa Rica, Lebanon, D R Congo, Vietnam, Yemen, Jordan etc.

The COVID-19 pandemic has intensified into a global crisis, driving the nation to enforce lock-down of all economic activity for the last few months. The Company has adhered to all recommended precautions/guidelines in its operations, which includes sanitization and hygiene, providing work from home facility to all employees, maximizing audio & video-conferencing and minimizing contact, closing employee travel and following all government directions on the subject.

Despite of such global crisis caused by the COVID-19 pandemic, the Company in the Current Financial Quarter and Half Year ended 30th September, 2020 has earned a profit of Rs. 77.30 Lakhs as compared to Rs. 3.28 Lakhs of the previous Financial Year ended 31<sup>st</sup> March, 2020.

During the Current Financial Quarter and Half Year ended 30th September, 2020 the Earning Per Share for continuing operations based on weighted average is 0.73 as compared to 0.03 of the previous financial year ended 31<sup>st</sup> March, 2020.

#### **CHAIRMAN'S MESSAGE:**

At Vaishali Pharma, we are working tirelessly to make available health improving pharmaceutical products affordable and accessible to all. Looking beyond this immediate term, the upcoming half year shall present more good opportunities for the Company and we shall perform better than the pervious half year.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects. One can count upon us for quality pharmaceutical and healthcare products.

For more details please visit: [www.vaishalipharma.com](http://www.vaishalipharma.com)

For any Investor Relations query, please contact:

**Mr. Atul Vasani**

**Managing Director**

**Vaishali Pharma Limited**

Email: [director@vaishalipharma.com](mailto:director@vaishalipharma.com)

**Note:** Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.